journal article·2023-04Open access

Mass production system for RNA-loaded lipid nanoparticles using piling up microfluidic devices

Masatoshi Maeki, Yuto Okada, Shuya Uno, Kaisei Sugiura, Yuichi Suzuki, Kento Okuda, Yusuke Sato, Masao Ando, Hiroyuki Yamazaki, Masaki Takeuchi, Akihiko Ishida, Hirofumi Tani, Hideyoshi Harashima, Manabu Tokeshi

Abstract

Microfluidic devices are widely used in lipid nanoparticle (LNP)-based vaccines and nanomedicine research. These devices should be stiff enough to withstand the high flow rate for the mass production of LNPs, and malleable enough to use when fabricating complicated microchannel or micromixer structures, such as staggering herringbone micromixers. Due to the limitations of the available fabrication methods, optimal microfluidic devices have not yet been developed. In this study, we report the development of a glass-based microfluidic device based on the invasive Lipid Nanoparticle Production (iLiNP) device® reported previously. The LNP size controllability of glass-based iLiNP device was similar to that of the poly(dimethylsiloxane) (PDMS)-based iLiNP device, and the glass-iLiNP device was used for mRNA-loaded LNP production with ionizable lipids used for COVID-19 mRNA vaccines. We also demonstrate a piling- and numbering-up strategy based on glass-iLiNP device. The iLiNP unit composed of five-layered microchannels was fabricated by piling-up each glass-iLiNP device followed by parallelization (numbering-up) for the mass production of LNPs. This iLiNP system can produce LNPs with sizes ranging between 20 and 60 nm at a flow rate of 20–50 mL/min, and its performance is comparable to that of the commercially available microfluidic system like NanoAssemblr®.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · SARS-CoV-2 and COVID-19 Research · Microfluidic and Bio-sensing Technologies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (43)

Show source-provided references
1. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
2. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant10.1056/NEJMoa2108891 ↗
3. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in qatar10.1038/s41591-021-01583-4 ↗
4. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months10.1056/NEJMoa2110345 ↗
5. Modified mRNA vaccines protect against Zika Virus infection10.1016/j.cell.2017.02.017 ↗
6. From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases10.1016/j.actbio.2021.06.023 ↗
7. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates10.1038/s41541-021-00307-6 ↗
8. Evaluation of extrusion technique for nanosizing liposomes10.3390/pharmaceutics8040036 ↗
9. Liposome: classification, preparation, and applications10.1186/1556-276X-8-102 ↗
10. Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems10.1016/j.addr.2018.03.008 ↗
11. Lipid Nanovesicles by microfluidics: manipulation, synthesis, and drug delivery
12. Lipid nanoparticles for drug delivery
13. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation10.1021/ja301621z ↗
14. Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing10.1021/la204833h ↗
15. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery10.1016/j.jconrel.2022.02.017 ↗
16. One-step production using a microfluidic device of highly biocompatible size-controlled noncationic exosome-like nanoparticles for RNA delivery10.1021/acsabm.0c01519 ↗
17. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs10.1038/s41565-019-0591-y ↗
18. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA10.1016/j.jconrel.2016.05.059 ↗
19. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery10.1016/j.jconrel.2016.03.019 ↗
20. Production of siRNA-loaded lipid nanoparticles using a microfluidic device
21. Microfluidic device-enabled mass production of lipid-based nanoparticles for applications in nanomedicine and cosmetics10.1021/acsanm.2c00886 ↗
22. Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers10.1371/journal.pone.0187962 ↗
23. Effects of flow-induced microfluidic chip wall deformation on imaging flow cytometry10.1002/cyto.a.23944 ↗
24. The deformation of flexible PDMS microchannels under a pressure driven flow10.1039/B813061B ↗
25. Glass based micro total analysis systems: materials, fabrication methods, and applications10.1016/j.snb.2021.129859 ↗
26. Effect of organic solvents on a production of PLGA-based drug-loaded nanoparticles using a microfluidic device10.1021/acsomega.2c03137 ↗
27. A simple and reversible glass-glass bonding method to construct a microfluidic device and its application for cell recovery10.1039/D1LC00058F ↗
28. Materials for microfluidic chip fabrication10.1021/ar300314s ↗
29. Intrinsic viscosity of polymers and biopolymers measured by microchip10.1021/ac050932r ↗
30. Three-dimensional, symmetrically assembled microfluidic device for lipid nanoparticle production10.1039/D0RA08826A ↗
31. Development of a microfluidic-based post-treatment process for size-controlled lipid nanoparticles and application to siRNA delivery10.1021/acsami.0c05489 ↗
32. Development of the iLiNP device: fine tuning the lipid nanoparticle size within 10nm for drug delivery10.1021/acsomega.8b00341 ↗
33. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability10.1016/j.ijpharm.2021.120586 ↗
34. NMR study of water molecules confined in extended nanospaces10.1002/anie.200604502 ↗
35. Pile-up glass microreactor10.1039/b208383n ↗
36. The use of design of experiments with multiple responses to determine optimal formulations for in vivo hepatic mRNA delivery10.1016/j.jconrel.2020.08.031 ↗
37. Nanomaterial delivery systems for mRNA vaccines
38. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs10.1016/j.dmpk.2021.100424 ↗
39. Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP: a case study using protein-loaded liposomes10.1016/j.ijpharm.2020.119266 ↗
40. Rapid and scale-independent microfluidic manufacture of liposomes entrapping protein incorporating in-line purification and at-line size monitoring10.1016/j.ijpharm.2018.11.060 ↗
41. Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device10.1021/acs.nanolett.1c01353 ↗
42. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo10.1016/j.jconrel.2019.01.001 ↗
43. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration10.1038/s42003-021-02441-2 ↗